Company profile
Biodexa Pharmaceuticals Plc
NASDAQ:BDRXBiotechnology: Pharmaceutical Preparations
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05324501 | phase1 | terminated | 2022-10-19 | 2024-09-10 | Biodexa Pharmaceuticals | A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma |
FDA applications (0)
No records yet.